CAS 150322-43-3|Prasugrel

Introduction：Basic information about CAS 150322-43-3|Prasugrel, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Prasugrel BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Articles48
6. Synonyms

Common Name	Prasugrel
CAS Number	150322-43-3	Molecular Weight	373.44100
Density	1.347	Boiling Point	493.5ºC at 760 mmHg
Molecular Formula	C₂₀H₂₀FNO₃S	Melting Point	122 °C
MSDS	ChineseUSA	Flash Point	252.3ºC

Names

Name	Prasugrel
Synonym	More Synonyms

Prasugrel BiologicalActivity

Description	Prasugrel is a platelet inhibitor with IC50 value of 1.8 μM.IC50 value:Target: P2Y12 receptorPrasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 μm. From Wikipedia
Related Catalog	Signaling Pathways >>GPCR/G Protein >>P2Y ReceptorResearch Areas >>Cardiovascular Disease
References	[1]. Pharmacokinetic basis of the antiplatelet action of prasugrel By Schroer, Karsten; Siller-Matula, Jolanta M.; Huber, Kurt From Fundamental & Clinical Pharmacology (2012), 26(1), 39-46. [2]. Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats By Sugidachi, Atsuhiro; Yamaguchi, Shinji; Jakubowski, Joseph A.; Ohno, Kosaku; Tomizawa, Atsuyuki; Hashimoto, Masami; Niitsu, Yoichi From Journal of Cardiovascular Pharmacology (2011), 58(3), 329-334. [3]. Darius H.Prasugrel.Hamostaseologie. 2012 Aug 1;32(3):186-90. [4]. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. [5]. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.Clin Sci (Lond). 2012 Nov 1;123(10):591-600.

Description

Prasugrel is a platelet inhibitor with IC50 value of 1.8 μM.IC50 value:Target: P2Y12 receptorPrasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 μm. From Wikipedia

Related Catalog

Signaling Pathways >>GPCR/G Protein >>P2Y ReceptorResearch Areas >>Cardiovascular Disease

References

[1]. Pharmacokinetic basis of the antiplatelet action of prasugrel By Schroer, Karsten; Siller-Matula, Jolanta M.; Huber, Kurt From Fundamental & Clinical Pharmacology (2012), 26(1), 39-46.

[2]. Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats By Sugidachi, Atsuhiro; Yamaguchi, Shinji; Jakubowski, Joseph A.; Ohno, Kosaku; Tomizawa, Atsuyuki; Hashimoto, Masami; Niitsu, Yoichi From Journal of Cardiovascular Pharmacology (2011), 58(3), 329-334.

[3]. Darius H.Prasugrel.Hamostaseologie. 2012 Aug 1;32(3):186-90.

[4]. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.J Am Coll Cardiol. 2012 Jul 17;60(3):193-9.

[5]. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.Clin Sci (Lond). 2012 Nov 1;123(10):591-600.

Chemical & Physical Properties

Density	1.347
Boiling Point	493.5ºC at 760 mmHg
Melting Point	122 °C
Molecular Formula	C₂₀H₂₀FNO₃S
Molecular Weight	373.44100
Flash Point	252.3ºC
Exact Mass	373.11500
PSA	74.85000
LogP	3.82890
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.619
InChIKey	DTGLZDAWLRGWQN-UHFFFAOYSA-N
SMILES	CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Storage condition	2-8°C

Safety Information

Hazard Codes	Xi
RIDADR	NONH for all modes of transport

Articles48

Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase.

PLoS ONE 9(10) , e110054, (2014)

Homocysteinylation of lysine residues by homocysteine thiolactone (HCTL), a reactive homocysteine metabolite, results in protein aggregation and malfunction, and is a well-known risk factor for cardio...

Effect of grapefruit juice on the bioactivation of prasugrel.

Br. J. Clin. Pharmacol. 80 , 139-45, (2015)

The P2Y12 inhibitor prasugrel is a prodrug, which is activated after its initial hydrolysis partly by cytochrome P450 (CYP) 3A4. Grapefruit juice, a strong inactivator of intestinal CYP3A4, greatly re...

Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials.

Int. J. Cardiol. 181 , 331-9, (2015)

Duration of dual antiplatelet therapy (DAPT) following drug-eluting stents (DES) remains controversial and is a topic of ongoing research.Direct and adjusted indirect comparisons of all the recent ran...

Synonyms

5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate

Prasugrel

Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-

Unii-34K66tbt99

Effient

Efient

Recommended......